SNDL (SNDL) Competitors

Tarsus Pharmaceuticals (NASDAQ:TARS) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends.

Does the media favor TARS or SNDL?

In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 4 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 0.87 beat SNDL's score of -0.14 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SNDL	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher valuation and earnings, TARS or SNDL?

SNDL has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than SNDL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$129.62M	14.11	-$135.89M	-$3.81	-12.56
SNDL	$911.22M	0.51	-$127.91M	-$0.31	-5.71

Do analysts rate TARS or SNDL?

Tarsus Pharmaceuticals presently has a consensus target price of $56.00, indicating a potential upside of 17.06%. SNDL has a consensus target price of $3.25, indicating a potential upside of 83.62%. Given SNDL's higher possible upside, analysts plainly believe SNDL is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
SNDL	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor TARS or SNDL?

SNDL received 93 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 72.31% of users gave SNDL an outperform vote while only 66.67% of users gave Tarsus Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Tarsus Pharmaceuticals	Outperform Votes 48 66.67%	Underperform Votes 24 33.33%
SNDL	Outperform Votes 141 72.31%	Underperform Votes 54 27.69%

Do institutionals and insiders hold more shares of TARS or SNDL?

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is TARS or SNDL more profitable?

SNDL has a net margin of -12.11% compared to Tarsus Pharmaceuticals' net margin of -103.64%. SNDL's return on equity of -8.27% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-103.64%	-55.86%	-39.28%
SNDL	-12.11%	-8.27%	-6.96%

Which has more risk & volatility, TARS or SNDL?

Tarsus Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, SNDL has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500.

Summary

SNDL beats Tarsus Pharmaceuticals on 11 of the 17 factors compared between the two stocks.